The mission of the Breast Cancer Program (BC) is to conduct high-impact breast cancer research through collaborations among its members and with members of other Cancer Center programs. With a portfolio of basic, translational, clinical and population-based research, BC focuses on three broad themes: Theme 1 is focused on understanding mechanisms of responsiveness to endocrine therapy. Key accomplishments in this theme include the award of a Center for Cancer Systems Biology that supported development of the first roadmap for mathematically modeling estrogen receptor signaling (Clarke). Theme 2 elucidates nutritional, environmental and genetic risk factors of breast cancer susceptibility. Noteworthy accomplishments include demonstrating the role of epigenetic modifications in establishing and maintaining transgenerational mammary cancer susceptibility in rats (Hilakivi-Clarke). Theme 3 explores clinical, therapeutic, molecular, and social factors that impact the treatment and progression of breast cancer. Key accomplishments include a study led by Swain that changed clinical practice by showing the survival benefit of adding pertuzumab to standard therapy in metastatic HER2 positive breast cancer. Led by Robert Clarke, PhD, DSc, and Claudine Isaacs, MD, the Program has 24 members representing eight Georgetown University departments and two MedStar hospitals. The Program also includes 10 breast cancer patient advocates. From 2009 to 2012, 42 therapeutic trials have accrued 231 patients. BC research is highly collaborative and interdisciplinary, and would not be possible outside of a Cancer Center that adds value through substantial institutional support ($11.6M) and access to nine state-of-the-art Shared Resources, all of which are used by BC members. Members are supported by $5.1M in peer-reviewed funding (direct cost), including $3.1 M of direct NCI funding. BC is home to three multi-investigator grants. Productivity is demonstrated by 357 cancer-related, peer-reviewed publications, of which 35% are intra- and/or interprogrammatic, the latter including collaborators from all three other Programs. 52% of publications involve external collaborations. Additional noteworthy features include: a strong junior investigator mentorship program;development of novel investigator-initiated clinical trials across MWHC and MGUH with correlative studies using cellular reprogramming and functional genomic technologies;and outreach and research initiatives in the Black and Hispanic communities within our catchment area.
Death rates from breast cancer are higher in the Washington, DC region than elsewhere in the U.S. and mortality is greater in Black women than in any other group. Thus, BC fills a great need through its emphasis on understanding mechanisms of responsiveness and risk factors that will address some of the unique cancer-related challenges in our catchment area.
|Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066|
|Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :|
|Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50|
|Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525|
|Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:|
|Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438|
|Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493|
|DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16|
|Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105|
|Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:|
Showing the most recent 10 out of 997 publications